Haemonetics (STU:HAZ) Valuation Rank


STU:HAZ Haemonetics Corp STU:HAZ
81 GF Score
Price €65.50
GF Value €74.38
! 4 Warning Signs
View Full Analysis

What is Haemonetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Haemonetics Valuation Rank Related Terms

STU:HAZ
81GF Score
Haemonetics Corp STU:HAZ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.9% below its estimated GF Value™ of €74.38.

Key valuation signals for STU:HAZ:

  • Valuation Rank:
  • GF Value™: €74.38 vs. price of €65.50 (11.9% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
81GF Score

Get the complete analysis for STU:HAZ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€74.38
GF Value